New hope for Hard-to-Treat breast cancer: phase 3 trial launches
NCT ID NCT07406542
First seen Feb 13, 2026 · Last updated May 24, 2026 · Updated 14 times
Summary
This study tests a new drug called SYS6010 against standard chemotherapy in people with advanced breast cancer that has not responded to previous treatments. The cancer must be HER2-negative and EGFR-positive. About 400 participants will be randomly assigned to receive either SYS6010 or a standard chemo drug. The goal is to see if SYS6010 can delay cancer growth and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.